ATE326469T1 - Pyrrolopyrimidine als mittel zur inhibierung von cysteinproteasen - Google Patents

Pyrrolopyrimidine als mittel zur inhibierung von cysteinproteasen

Info

Publication number
ATE326469T1
ATE326469T1 AT02797553T AT02797553T ATE326469T1 AT E326469 T1 ATE326469 T1 AT E326469T1 AT 02797553 T AT02797553 T AT 02797553T AT 02797553 T AT02797553 T AT 02797553T AT E326469 T1 ATE326469 T1 AT E326469T1
Authority
AT
Austria
Prior art keywords
pyrrolopyrimidines
agent
cysteine proteases
inhibiting cysteine
inhibiting
Prior art date
Application number
AT02797553T
Other languages
English (en)
Inventor
Claudia Betschart
Kenji Hayakawa
Osamu Irie
Junichi Sakaki
Genji Iwasaki
Rene Lattmann
Martin Missbach
Naoki Teno
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE326469T1 publication Critical patent/ATE326469T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02797553T 2001-08-30 2002-08-29 Pyrrolopyrimidine als mittel zur inhibierung von cysteinproteasen ATE326469T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0121033.5A GB0121033D0 (en) 2001-08-30 2001-08-30 Organic compounds

Publications (1)

Publication Number Publication Date
ATE326469T1 true ATE326469T1 (de) 2006-06-15

Family

ID=9921234

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02797553T ATE326469T1 (de) 2001-08-30 2002-08-29 Pyrrolopyrimidine als mittel zur inhibierung von cysteinproteasen

Country Status (30)

Country Link
US (2) US7452886B2 (de)
EP (1) EP1423391B8 (de)
JP (1) JP4629334B2 (de)
KR (1) KR100695845B1 (de)
CN (1) CN100372849C (de)
AR (1) AR036374A1 (de)
AT (1) ATE326469T1 (de)
AU (1) AU2002333760B2 (de)
BR (1) BR0212226A (de)
CA (1) CA2458684C (de)
CY (1) CY1105573T1 (de)
DE (1) DE60211530T2 (de)
DK (1) DK1423391T3 (de)
EC (1) ECSP044998A (de)
ES (1) ES2262888T3 (de)
GB (1) GB0121033D0 (de)
HK (1) HK1072254A1 (de)
HU (1) HUP0401301A3 (de)
IL (3) IL160367A0 (de)
MX (1) MXPA04001935A (de)
MY (1) MY157368A (de)
NO (1) NO328890B1 (de)
NZ (1) NZ531343A (de)
PE (1) PE20030418A1 (de)
PL (1) PL368280A1 (de)
PT (1) PT1423391E (de)
RU (1) RU2331644C2 (de)
TW (1) TWI297690B (de)
WO (1) WO2003020721A1 (de)
ZA (1) ZA200401042B (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
SE0201980D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
GB0220187D0 (en) 2002-08-30 2002-10-09 Novartis Ag Organic compounds
PL375053A1 (en) 2002-09-24 2005-11-14 Novartis Ag Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
AR043692A1 (es) * 2003-02-06 2005-08-10 Novartis Ag 2-cianopirrolopirimidinas y sus usos farmaceuticos
GB0304640D0 (en) * 2003-02-28 2003-04-02 Novartis Ag Organic compounds
EP1619193A4 (de) * 2003-04-18 2010-08-11 Ono Pharmaceutical Co Spiropiperidinverbindung und deren medizinische verwendung
BRPI0409868A (pt) * 2003-04-28 2006-05-16 Novartis Ag composição farmacêutica que compreende um inibidor da catepsina s e um opióide
EP1797883A3 (de) * 2003-04-28 2007-08-01 Novartis AG Pharmezeutische Zusammensetzung einen Cathepsin S Inhibitor und ein Opioid enthaltend
AU2004237745A1 (en) * 2003-04-30 2004-11-18 Bayer Cropscience Ag Insecticidal (dihalopropenyl) phenylalkyl substituted dihydrobenzofuran and dihydrobenzopyran derivatives
WO2005011703A1 (en) * 2003-08-04 2005-02-10 Akzo Nobel N.V. 2-cyano-1,3,5-triazine-4,6-diamine derivatives
EP1786816A4 (de) 2003-09-10 2009-11-04 Virochem Pharma Inc Spirohydantoinverbindungen und -verfahren zur modulation von chemokin-rezeptoraktivität
CA2556263A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
WO2005085210A1 (ja) * 2004-03-10 2005-09-15 Ono Pharmaceutical Co., Ltd. ニトリル化合物およびその化合物を有効成分として含有する医薬組成物
ES2251292B1 (es) * 2004-04-20 2007-07-01 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
AU2005243238B2 (en) 2004-05-03 2011-11-10 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (SARMS)
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
WO2006022454A1 (ja) 2004-08-27 2006-03-02 Ono Pharmaceutical Co., Ltd 塩基性基を含有する化合物およびその用途
KR100651849B1 (ko) * 2005-02-01 2006-12-01 엘지전자 주식회사 세탁기
CA2617725C (en) * 2005-08-05 2012-04-03 Hybrigenics Sa Novel cysteine protease inhibitors and their therapeutic applications
EP1933860A2 (de) 2005-09-01 2008-06-25 Ares Trading S.A. Behandlung von optikusneuritis
TW200745055A (en) * 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
US7326715B2 (en) 2005-09-23 2008-02-05 N.V. Organon 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
TW200732314A (en) * 2005-10-26 2007-09-01 Smithkline Beecham Corp Substituted thiazoles and their use
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
TW200804382A (en) * 2005-12-05 2008-01-16 Incyte Corp Lactam compounds and methods of using the same
US7687515B2 (en) 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
EP2042503B1 (de) 2006-05-16 2013-01-30 Ono Pharmaceutical Co., Ltd. Verbindung mit gegebenenfalls geschützter acider gruppe und anwendung davon
JP2010503656A (ja) 2006-09-13 2010-02-04 アストラゼネカ アクチボラグ スピロ−オキサゾリジノン化合物と代謝共役型グルタミン酸受容体ポテンシエーターとしてのその使用
TW200911803A (en) * 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
US7932251B2 (en) 2007-07-16 2011-04-26 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
CL2008003085A1 (es) 2007-10-19 2009-10-09 Astrazeneca Ab Compuestos derivados de 4-metil-5-[1-(2-(3-metilfenil)-2h-tetrazol-5-il)etoxi]-4h-1,2,4-triazol-3-il moduladores del receptor mglur5; composiciones farmceuticas que los contienen; compuestos intermediarios; y su uso en la preparacion de un medicamento util en el tratamiento de desordenes neurologicos, psiquiatricos o gastrointestinales.
RU2562571C2 (ru) 2008-06-20 2015-09-10 Новартис Аг Педиатрические композиции для лечения рассеянного склероза
TW201035094A (en) 2009-01-16 2010-10-01 Organon Nv 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
US8026236B2 (en) 2009-01-16 2011-09-27 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
KR101763656B1 (ko) 2009-06-29 2017-08-01 인사이트 홀딩스 코포레이션 Ｐｉ3ｋ 저해물질로서의 피리미디논
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
AU2010339444A1 (en) 2009-12-30 2012-07-19 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
WO2011086125A1 (en) 2010-01-15 2011-07-21 N.V. Organon 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES
JP5816678B2 (ja) 2010-04-14 2015-11-18 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ＰＩ３Ｋδ阻害剤としての縮合誘導体
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
DK2626431T3 (en) 2010-10-06 2015-12-21 Fundació Inst De Recerca Biomèdica Irb Barcelona A process for the diagnosis, prognosis and treatment of breast cancer metastasis
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
WO2013033569A1 (en) 2011-09-02 2013-03-07 Incyte Corporation Heterocyclylamines as pi3k inhibitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2650682A1 (de) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Asymmetrische Ester von als Schmiermittel geeigneten Fettsäuren
EP2840083B1 (de) * 2012-04-17 2017-09-13 Astellas Pharma Inc. Nitrogenierte bicyclische aromatische heterocyclische verbindung
EP2859120B1 (de) 2012-06-06 2018-11-14 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Verfahren zur diagnose und prognose von lungenkrebsmetastasen
ES2744244T3 (es) 2012-10-12 2020-02-24 Inbiomotion Sl Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-MAF
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
AU2014229505B2 (en) 2013-03-15 2020-02-27 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
MX362041B (es) 2013-10-09 2019-01-07 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama.
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
CA2967224C (en) 2014-12-11 2023-08-22 Inbiomotion S.L. Binding members for human c-maf
NZ734993A (en) 2015-02-27 2024-03-22 Incyte Holdings Corp Salts of pi3k inhibitor and processes for their preparation
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
KR20230128144A (ko) 2016-05-25 2023-09-01 인바이오모션 에스.엘. c-MAF 상태에 기초한 유방암의 치료
CA3082728A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
KR102054910B1 (ko) * 2017-12-19 2019-12-12 한림제약(주) 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
EP3556760A1 (de) * 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiroverbindungen
CN112312904A (zh) 2018-04-16 2021-02-02 C4医药公司 螺环化合物
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
WO2022226166A1 (en) * 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1251074B (de) 1960-11-02 1967-09-28 J R Geigy A -G , Basel (Schweiz) Selektives Herbizid
CH627919A5 (de) 1977-04-14 1982-02-15 Ciba Geigy Ag Herbizide mittel.
US5958930A (en) * 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
DK0682027T3 (da) * 1994-05-03 1998-05-04 Ciba Geigy Ag Pyrrolopyrimidinderivater med antiproliferativ virkning
US5683999A (en) * 1995-03-17 1997-11-04 The Dupont Merck Pharmaceutical Company Cyclic urea HIV protease inhibitors
IL131582A0 (en) * 1997-03-19 2001-01-28 Basf Ag Pyrrolo [2,3d] pyrimidines and their use as tyrosine kinase inhibitors
EP1091738B1 (de) * 1998-06-30 2006-12-06 Eli Lilly And Company BICYCLISCHE sPLA 2-INHIBITOREN
PL346700A1 (en) * 1998-09-18 2002-02-25 Basf Ag Pyrrolopyrimidines as protein kinase inhibitors
CN1195755C (zh) * 1999-12-10 2005-04-06 辉瑞产品公司 吡咯并[2,3－d]嘧啶化合物
US20030225036A1 (en) * 2000-03-20 2003-12-04 Aleksandr Kolesnikov Non-amidine containing protease inhibitors
CN1657523A (zh) 2000-04-28 2005-08-24 田边制药株式会社 环状化合物

Also Published As

Publication number Publication date
JP2005502683A (ja) 2005-01-27
MY157368A (en) 2016-06-15
RU2331644C2 (ru) 2008-08-20
WO2003020721A1 (en) 2003-03-13
DE60211530D1 (de) 2006-06-22
TWI297690B (en) 2008-06-11
CA2458684A1 (en) 2003-03-13
CN100372849C (zh) 2008-03-05
RU2004109815A (ru) 2005-10-20
EP1423391B8 (de) 2007-12-12
HK1072254A1 (en) 2005-08-19
CN1549817A (zh) 2004-11-24
NO328890B1 (no) 2010-06-07
ES2262888T3 (es) 2006-12-01
IL198643A (en) 2010-12-30
GB0121033D0 (en) 2001-10-24
AU2002333760B2 (en) 2007-01-04
PE20030418A1 (es) 2003-06-12
MXPA04001935A (es) 2004-06-15
KR100695845B1 (ko) 2007-03-20
NO20041180L (no) 2004-03-19
HUP0401301A2 (hu) 2004-10-28
ECSP044998A (es) 2004-04-28
ZA200401042B (en) 2004-10-25
US20090054467A1 (en) 2009-02-26
PL368280A1 (en) 2005-03-21
HUP0401301A3 (en) 2008-03-28
DE60211530T2 (de) 2006-12-21
CA2458684C (en) 2009-04-07
DK1423391T3 (da) 2006-09-25
AR036374A1 (es) 2004-09-01
KR20040029123A (ko) 2004-04-03
US20050054851A1 (en) 2005-03-10
CY1105573T1 (el) 2010-07-28
IL160367A (en) 2009-12-24
BR0212226A (pt) 2004-08-17
EP1423391B1 (de) 2006-05-17
JP4629334B2 (ja) 2011-02-09
IL160367A0 (en) 2004-07-25
US7452886B2 (en) 2008-11-18
PT1423391E (pt) 2006-09-29
NZ531343A (en) 2006-01-27
EP1423391A1 (de) 2004-06-02

Similar Documents

Publication Publication Date Title
ATE326469T1 (de) Pyrrolopyrimidine als mittel zur inhibierung von cysteinproteasen
ATE411316T1 (de) Pyrrolopyrimidine als phosphodiesterase-vii- hemmer
NO2019048I1 (no) Denosumab
ATE397925T1 (de) Cis-imidazoline als mdm2-hemmer
ATE547412T1 (de) Inhibitoren von serinproteasen, insbesondere hcv- ns3-ns4a-protease
ATE380812T1 (de) Stickstoffhaltige, bicyclische heterocyclen zur verwendung als antibakterielle mittel
ATE393629T1 (de) Verwendung von cci-779 als antineoplastisches mittel
PT1370553E (pt) Inibidores de rhoquinase
ATE335722T1 (de) Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel
HUP0400300A2 (en) Pyrrolopyrimidines as protein kinase inhibitors
NO20042000D0 (no) Fremgangsmate for flerbrukerinnhold
MXPA03007310A (es) Derivados de ftalazinona piperidino como inhibidores pde4.
NO20035728D0 (no) Pyrrolopyrimidiner som proteinkinaseinhibitorer
DE50204020D1 (de) Mikrotom
PL370766A1 (en) Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
DE60200527D1 (de) Abnehmbare Mittelkonsole
DE502004006055D1 (de) 6-arylamino-5-cyano-4-pyrimidinone als pde9a-inhibitoren
DE60218612D1 (de) Schleifscheiben
ATE454051T1 (de) Nahrungsmittel enthaltend sättigungsmittel
DE60202489D1 (de) Lysin enthaltende kautablette
ATE429431T1 (de) 2-amino-benzoxazol-suphonamide als breitspektrum- hiv-protease-inhibitoren
DE602004026773D1 (de) Verfahrensherstellung von ethern
ITSV20030016A1 (it) Sostanze contenenti tannini o miscele di tannini.
DE60201463D1 (de) Indanon-Derivate als Duftstoffe
ATE369137T1 (de) Lyophilisierte formulierung enthaltend olanzapin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1423391

Country of ref document: EP